|
1
|
Shamaki GR, Soji-Ayoade D, Adedokun SD, Kesiena O, Favour M, Bolaji O, Ezeh EO, Okoh N, Sadiq AA, Baldawi H, Davis A, Bob-Manuel T. Endovascular Venous Interventions - A State-of-the-Art Review. Curr Probl Cardiol 2023; 48:101534. [PMID: 36481393 DOI: 10.1016/j.cpcardiol.2022.101534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 12/01/2022] [Indexed: 12/12/2022]
Abstract
Venous vascular diseases are an important clinical entity estimated to affect several million people worldwide. Deep vein thrombosis (DVT) is a common venous disease with a population variable prevalence of 122 to 160 persons per 100,000 per year, whereas pulmonary embolism (PE) affects up to 60 to 70 per 100 000 and carries much higher mortality. Chronic venous diseases, which cause symptoms like leg swelling, heaviness, pain, and discomfort, are most prevalent in the elderly and significantly impact their quality of life. Some estimate that chronic vascular diseases account for up to 2% of healthcare budgets in Western countries. Treating venous vascular disease includes using systemic anticoagulation and interventional therapies in some patient subsets. In this comprehensive review, we discuss endovascular treatment modalities in the management of venous vascular diseases.
Collapse
Affiliation(s)
| | | | | | - Onoriode Kesiena
- Department of Internal Medicine, Piedmont Athens Regional Medical Center, Athens, GA
| | - Markson Favour
- Department of Internal Medicine, Lincoln Medical Centre Bronx, NY
| | - Olayiwola Bolaji
- Department of Internal Medicine, University of Maryland Capital Region Medical Center, Largo, MD
| | | | - Nelson Okoh
- Department of Internal Medicine, Rutgers Community Hospital West Toms Rivers, NJ
| | | | - Harith Baldawi
- Department of Internal Medicine, Ochsner Clinic Foundation, Orleans, LA
| | - Arthur Davis
- Department of Internal Medicine, Ochsner Clinic Foundation, Orleans, LA
| | | |
Collapse
|
|
2
|
Interventional Management of Chronic Thromboembolic Pulmonary Hypertension. Cardiol Clin 2021; 40:103-114. [PMID: 34809911 DOI: 10.1016/j.ccl.2021.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Chronic thromboembolic pulmonary hypertension is a distinct form of pulmonary hypertension characterized by the nonresolution of thrombotic material in the pulmonary tree; whenever feasible and safe, first-line treatment should be pulmonary thromboendarterectomy. In patients who are not operative candidates, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment modality that results in improvements in functional class, symptoms, hemodynamics, 6-minute walk distance, and right ventricular and pulmonary artery mechanics. Careful attention to procedural technique and rapid identification and treatment of complications are critical for a successful BPA program.
Collapse
|